Early ADT for Incurable Prostate Cancer Has Limited Impact on QOL
Immediate treatment with androgen-deprivation therapy (ADT) for men with asymptomatic non-curable prostate cancer did not have major effects on quality... Read More
Prostate Cancer Patients Can Improve Bone Health With Osteoporosis Medications
Men with non-metastatic prostate cancer who receive androgen deprivation therapy (ADT) risk loss of bone mineral density (BMD) and fractures,... Read More
New ASCO Guideline on Second-Line Hormone Therapy in Prostate Cancer
The American Society of Clinical Oncology (ASCO) issued the first guidance, a provisional clinical opinion (PCO), on second-line hormonal therapy... Read More
Current Guidelines Miss Relevant Germline Mutations in Prostate Cancer
National Comprehensive Cancer Network (NCCN) genetic testing guidelines and Gleason scores do not predict which patients with prostate cancer will... Read More
Marker in Prostate Cancer Fails to Predict Response to PARP Inhibition
Maha H. Hussain, MD, of the Lurie Cancer Center in Chicago, discusses clinical and genomics data from the NCI 9012... Read More
‘High-Intensity’ Sequencing Detected Breast, Prostate Cancers in Blood
A novel high-intensity sequencing approach enabled broad detection of genomic variants in plasma with high rates of concordance with corresponding... Read More
Reducing ADT to 18 Months May Be Sufficient in High-Risk Prostate Cancer
Androgen deprivation therapy (ADT) can be safely reduced from 36 months to 18 months in high-risk prostate cancer, according to... Read More
Does ERG Expression Predict Docetaxel Benefit in Prostate Cancer?
Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy (ADT), according to... Read More
Addressing Physical, Cognitive Effects of ADT in Prostate Cancer Patients
At this year’s American Society of Clinical Oncology (ASCO) Annual meeting, Alicia K. Morgans, MD, assistant professor of medicine in... Read More
Prostate Cancer Molecular Subtyping Groups Tumors by Prognosis, Response
Molecular subtyping of prostate cancer into three categories—luminal A, luminal B, and basal—identifies differences in prognosis and response to treatment,... Read More